Clinical Trial Update: Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of MEK inhibitor trametinib and BRAF V600E inhibitor dabrafenib with radioactive iodine in patients with metastatic d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation | Phase 2 | Status: COMPLETED